2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
…, T Jaarsma, EA Jankowska, M Lainscak… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and …
…, T Jaarsma, EA Jankowska, M Lainscak… - European Heart …, 2023 - academic.oup.com
… , including patients with eGFR 20–45 mL/min/1.73 m 2 , even in the absence of albuminuria,
or with an eGFR of 45–90 mL/min/1.73 m 2 and a urinary albumin-to-creatinine ratio ≥200 …
or with an eGFR of 45–90 mL/min/1.73 m 2 and a urinary albumin-to-creatinine ratio ≥200 …
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart …
…, EA Jankowska, MS Anker, M Lainscak… - European journal of …, 2019 - Wiley Online Library
The European Society of Cardiology (ESC) has published a series of guidelines on heart
failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information …
failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
…, T Jaarsma, EA Jankowska, M Lainscak… - European journal of …, 2022 - Wiley Online Library
Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P.
Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor …
Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor …
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind …
…, M Lainscak, KB Seung, P Commerford, M Dellborg… - The Lancet, 2017 - thelancet.com
Background Inflammation in the tumour microenvironment mediated by interleukin 1β is
hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did …
hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did …
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart …
O Chioncel, M Lainscak, PM Seferovic… - European journal of …, 2017 - Wiley Online Library
Aims The objectives of the present study were to describe epidemiology and outcomes in
ambulatory heart failure ( HF ) patients stratified by left ventricular ejection fraction ( LVEF ) and …
ambulatory heart failure ( HF ) patients stratified by left ventricular ejection fraction ( LVEF ) and …
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS …
…, M Lainscak, KB Seung, P Commerford, M Dellborg… - The Lancet, 2018 - thelancet.com
Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is …
inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is …
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the …
…, J Hradec, A Kavoliuniene, M Lainscak… - European journal of …, 2013 - Wiley Online Library
Aims To evaluate how recommendations of European guidelines regarding pharmacological
and non‐pharmacological treatments for heart failure (HF) are adopted in clinical practice. …
and non‐pharmacological treatments for heart failure (HF) are adopted in clinical practice. …
European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions
…, M Hassanein, O Chioncel, M Lainscak… - European journal of …, 2016 - Wiley Online Library
Aims The European Society of Cardiology Heart Failure Long‐Term Registry ( ESC‐HF‐LT ‐R)
was set up with the aim of describing the clinical epidemiology and the 1‐year outcomes …
was set up with the aim of describing the clinical epidemiology and the 1‐year outcomes …
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
…, DJ Van Veldhuisen, M Lainscak… - European journal of …, 2018 - Wiley Online Library
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) and …
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) and …